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Abstract
Background: Recent studies have suggested that cardiometabolic index (CMI), a novel estimate of visceral adipose
tissue, could be of use in the evaluation of cardiovascular risk factors. However, the potential utility and clinical
significance of CMI in the detection of reduced estimated glomerular filtration rate (eGFR) remains uncertain. The
purpose of this study was to investigate the usefulness of CMI in assessing reduced eGFR in the general Chinese
population.
Methods: This cross-sectional analysis included 11,578 participants (mean age: 53.8 years, 53.7% females) from
Northeast China Rural Cardiovascular Health Study (NCRCHS) of general Chinese population (data collected from
January 2013 to August 2013). CMI was calculated by triglyceride to high density lipoprotein cholesterol ratio
multiply waist-to-height ratio. Reduced eGFR was defined as eGFR< 60 ml/min per 1.73m2. Multivariate regressions
were performed to determine CMI’s association with eGFR value and eGFR reduction, ROC analyses were employed
to investigate CMI’s discriminating ability for decreased eGFR.
Results: The prevalence of reduced eGFR was 1.7% in males and 2.5% in females. CMI was notably more adverse in
reduced eGFR groups, regardless of genders. In fully adjusted multivariate linear models, each 1 SD increment of
CMI caused 3.150 ml/min per 1.73m2 and 2.411 ml/min per 1.73m2 loss of eGFR before CMI reached 1.210 and
1.520 in males and females, respectively. In logistic regression analyses, per 1 SD increase of CMI brought 51.6%
additional risk of reduced eGFR in males while caused 1.347 times of risk in females. After divided into quartiles,
people in the top quartile of CMI had higher adjusted ORs of having reduced eGFR, with ORs of 4.227 (1.681, 10.
627) and 3.442 (1.685–7.031) for males and females respectively. AUC of CMI was revealed to be 0.633 (0.620–0.646)
in males and 0.684 (0.672–0.695) in females.
Conclusions: Higher CMI was independently associated with greater burden of reduced eGFR, highlighting VAT
distribution and dysfunction as a potential mechanism underlying the association of obesity with kidney damage
and adverse cardiovascular outcomes. The findings from this study provided important insights regarding the
potential usefulness and clinical relevance of CMI in the detection of reduced eGFR among general Chinese
population.
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Background
Chronic kidney disease (CKD) was a disease with
heterogeneous etiology that caused 15.8 deaths per
100,000 people worldwide in 2013 and was estimated to
attack 119.5 million Chinese people in the year of 2012
[1, 2]. Besides, CKD has been identified to be related
with multiple cardiovascular risk factors like hyperten-
sion and diabetes mellitus (DM), revealing its close as-
sociation with cardiovascular health [3, 4]. Therefore,
CKD has brought great burden to the health-care work
and economy [5, 6]. Knowing the poor outcomes and
high cost that caused by CKD as a worldwide public
health problem, it is a good choice to focus on the early
detection of reduced estimated glomerular filtration
rate (eGFR) for avoiding the progression of CKD. Ac-
cordingly, early detection of reduced eGFR is critically
needed for timely CKD prevention and overall improve-
ment in prognosis.
There is an wealthy evidence that dyslipidemia and
obesity are strongly related to the deterioration of renal
function, even in the early stage [7, 8]. Dyslipidemia in
CKD often exhibits a pattern of increased triglyceride
(TG) levels and decreased high density lipoprotein
cholesterol (HDL-C) levels [7]. Findings revealed that
increased TG level was significantly correlated with
CKD [9–11]. Furthermore, as a combination of 2 char-
acteristics of dyslipidemia in CKD, TG to HDL-C ratio
(TG / HDL-C) has also been identified to strongly asso-
ciated with decline of eGFR in participants without
CKD and rapid decrement of eGFR in participants with
CKD [12–14]. Obesity is another condition that
strongly correlated with decreased eGFR or CKD [8, 15].
As the most widely used index of obesity, body mass index
(BMI) was revealed to correlated with reduced eGFR,
CKD and end stage renal disease (ESRD) [16, 17]. How-
ever, BMI did not take abdominal obesity into consider-
ation when reflecting obesity status. Therefore, some
indexes such as waist circumference (WC) and
waist-to-height ratio (WHtR) were designed to be mea-
surements of central obesity [18]. And they have
already showed strong associations with CKD [19–22].
Nevertheless, comparisons between BMI, WC and
WHtR did not provide sufficient evidence for anyone of
them to be a premier marker of CKD with great sensi-
tivity or specificity [19–22]. Moreover, indexes of ab-
dominal obesity were insufficient to detecting visceral
adipose tissue (VAT), which was elucidated to possess a
more adverse effect on CKD development than sub-
cutaneous adipose tissue (SAT) [23, 24]. However, when
cooperating with aforementioned indexes of dyslipidemia,
their strength to discriminating VAT got reinforcement
[24]. Taken together, combination of dyslipidemia and ab-
dominal obesity could improve the identification of VAT
and therefore refine the detecting of reduced eGFR.
Recently, a novel marker named “cardiometabolic index
(CMI)” has been put forward by Ichiro Wakabayashi
[25]. CMI can be considered as an ideal marker to
recognize VAT because of its integration of dyslipid-
emia and abdominal obesity. This emerging marker has
been shown in several studies to be a useful screening
tool for various populations, identifying those with a
deteriorated metabolic profile and higher risk for car-
diovascular disease, such as left ventricular geometry
abnormalities, hyperuricemia, diabetes, hypertension,
and ischemic stroke [25–29]. It is unclear, however, if
CMI can be an identifier of reduced eGFR, independent
of cardiovascular risk factors and hypertension. Accord-
ingly, the present study was designed to test whether or
not higher CMI increase the risk of reduced eGFR in
the general Chinese population.
Methods
Study population
This study was part of a large cross-sectional population-
based epidemiological investigation that described the
prevalence, incidence, and natural history of cardiovascu-
lar risk factors among 11,956 permanent residents
(≥35 years of age) in rural areas of China from January
2012 to August 2013. The full details regarding the design
and rationale of the study were extensively described else-
where [26, 30, 31]. Briefly, the study adopted a multistage,
stratified random cluster-sampling scheme. In the first
stage, 3 counties (Dawa, Zhangwu, and Liaoyang County)
were selected from the eastern, southern, and northern
region of Liaoning province. In the second stage, 1 town
was randomly selected from each county (a total of 3
towns). In the third stage, 8 to 10 rural villages from each
town were randomly selected (a total of 26 rural villages).
Participants with pregnancy, malignant tumor, or mental
disorder were excluded from the present study. The study
protocol complied with the Second Helsinki Declaration
(and recent amendments) and was approved by the Ethics
Committee of China Medical University (Shenyang,
China), and all study participants provided written in-
formed consent. Patients with missing data for any of
CMI components or other variables analyzed in the study
(n = 378) were excluded. Accordingly, the final study co-
hort was composed of 11,578 subjects.
Data collection and measurements
Detailed process about data collection and measure-
ments was described by previous publications from our
research team that involved in the same survey as this
study [26, 30, 31]. Cardiologists and nurses completed a
training and passed a test before they were allowed to
conduct the questionnaire which collected informa-
tion about demographic data, health-related behavior,
anthropometric parameters, dietary condition, current
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medicine usage condition, history of cardiovascular
disease (CVD).
A carefully designed questionnaire was used to collect
data from subjects. A central steering committee with a
subcommittee conducted the quality control of the infor-
mation collection process. Subjects were divided into two
groups: Han and others. Education level was regarded as
three ordinal groups: primary school or below, middle
school, high school or above. Three ordinal groups (≤5000
CNY,5000–20,000 CNY,> 20,000 CNY) were utilized to
represent the family annual income level. Diet score was
calculated according to the collected information about
vegetable and meat consumption, a lower score meant
lower meat consumption and higher vegetable consump-
tion. Detailed information about diet score has been re-
ported in a prior study from our team [32]. Physical
activity level was acquired in both work and off hours,
and divided into three levels (low, middle, high). Messages
of current smoking and alcohol intake status were col-
lected through a series of questions about smoking and
drinking history of participants. Medicine usage such as
anti-hypertensive, anti-diabetic and lipid-lowering drugs
was recorded in the questionnaire as well. History of CVD
included coronary heart disease, arrhythmia, heart failure,
and stroke. Meanwhile, history of kidney disease was de-
fined as nephritis, kidney dysfunction, renal stones, renal
tumor, and autoimmune kidney disease.
After subjects completed a 5 min rest in sitting position
with relaxation, two randomly selected trained medical
staffs performed the blood pressure measurements for
them. Three consecutive readings were recorded and their
mean value was taken into statistical analyses.
With regard to the measurements of anthropometric
indices, subjects were requested to wear in light clothing
without shoes. Standard weight was measured to the
nearest 0.1 kg by using a calibrated digital scale. Subjects
held in a standing position when a calibrated stadi-
ometer was used to quantify their standard height to the
nearest 0.1 cm. As for the measurement of WC, elastic
measuring tapes was used to get the readings in a hori-
zontal position at 1 cm above the umbilicus. All of the
above measurements were performed twice and their
mean values were used for analyses.
Detailed delineation of the process of storage and
methods of laboratory measurements was reported in
our previous studies [26, 30, 31]. Briefly, fasting (12 h
overnight) blood samples were collected through
venipuncture. And these samples were separated and
frozen at − 20 °C within 1 h after the collection, and
then transported to a laboratory with certification for
examination. An Olympus AU 640 auto analyzer (Olympus,
Kobe, Japan) was used for biochemical analyses. All labora-
tory equipment was calibrated and blinded duplicate sam-
ples were used.
Definitions
BMI was calculated as mean weight divided by mean
height squared (kg/m2). WHtR was acquired as WC di-
vided by mean height. CMI was obtained by the following
equation [25]: CMI = TG/HDL-C ×WHtR. lipid accumu-
lation product (LAP) was calculated according to the
sex-specific formula [33]: LAP = TG (mmol/L) × [WC
(cm)-58] for females and LAP = TG (mmol/L) × [WC
(cm)-65] for males. And visceral adiposity index (VAI) was
determined by using the following formula [34]: Males:
VAI = [WC / 39.68 + (1.88 × BMI)] × (TG / 1.03) × (1.31 /
HDL); Females: VAI = [WC / 36.58 + (1.89 × BMI)] × (TG /
0.81) × (1.52/HDL).
eGFR was calculated according to CKD-EPI equation
[35]. Reduced eGFR was defined as eGFR < 60 ml/min
per 1.73m2 [36]. Diagnostic criteria of hypertension were
mean systolic blood pressure (SBP) equal to or greater
than 140 mmHg and/or diastolic blood pressure (DBP)
at least 90 mmHg and/or participants who were on anti-
hypertensive medications or self-reported previous
diagnosed hypertension [37]. Diagnosis of diabetes based
on the American Diabetes Association criteria: fasting
plasma glucose (FPG) ≥ 7.0 mmol/L and/or self-reported
previous diagnosis history or receiving plasma glucose
lowering therapy [38].
Statistical analyses
Analyses were performed in a sex-specific manner.
Continuous variables were expressed as mean values ±
standard deviation (SD) or as median (interquartile range)
if appropriate. Categorical variables were depicted as
frequencies (percentages). Continuous variables were
compared between groups with Student’s t test or
Mann-Whitney test according to their distribution, in
the meantime, categorical variables were also compared
between groups by using χ2 test [39]. As for the com-
parison of ordinal categorical variables (education level,
family annual income, physical activity), rank-sum test
was performed in order to get full utilization of the or-
dinal information. Before inferential analyses, CMI
values were log transformed due to highly skewed dis-
tributions. The chi-square linear-by-linear association
test was used to reveal linear trends across the quartiles
of CMI for percentages of prevalence of reduced eGFR.
Multivariate linear regression analysis was conducted to
evaluate the independent effect of CMI on eGFR value.
And logarithmic likelihood ratio test was employed to
compare the one-line linear regression model with a
two-piecewise linear model. Furthermore, multivariate
logistic regression analysis was performed to explore
the isolated association of CMI as a continuous variable
and as quartiles with the prevalence of reduced eGFR.
Sex-specific odds ratios (ORs) for every SD change of
CMI to identify the risk of reduced eGFR were acquired,
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the results were displayed as ORs and 95% confidence
intervals (95% CI). Lastly, receiver-operating character-
istic (ROC) curve was employed to investigate the opti-
mal cut-off value of CMI to detect the presence of
reduced eGFR. Area under the curve (AUC) was used
to compare the discriminating ability of CMI and other
indexes. All of the statistical analyses involved were
performed by SPSS 25.0 software (IBM corp), statistical
software packages R (http://www.R-project.org, The R
Foundation) and EmpowerStats (http://www.empower-
stats.com, X&Y Solutions, Inc., Boston, MA), Prism 7.0
software (Graphpad software, Inc) and MedCalc version
18.5 (MedCalc software, Belgium), a two-tailed P value
less than 0.05 indicated statistical significant.
Results
After excluding ineligible participants, we finally took
11,578 subjects into analyses, the results were shown in
Table 1. Of these subjects, 46.3% were males. The mean
age of total population was 53.8 years while people with
eGFR decrement were elder than their counterparts in
both genders. The prevalence of reduced eGFR was 1.7%
in males while females exhibited a higher rate of 2.5%.
As for the demographic information, education level,
family annual income, diet score and physical activity ex-
hibited significant lower levels in patients with reduced
eGFR. Contradictorily, female patients were more likely
to smoke at present but male patients tended not to be a
current smoker. Only males showed significant differ-
ence on alcoholic status between groups, but the results
revealed that normal eGFR subjects had greater possibil-
ity to be a current drinker. With regard to laboratory
test results, FPG, serum uric acid, TG and TG/HDL-C
confirmed a remarkable augmentation among eGFR dec-
rement patients, together with a dramatically decline of
HDL-C in patients. SBP, height, WC, WHtR showed
great increment when comparing CKD patients with
their counterparts regardless of sex. But DBP only exhib-
ited higher level in male patients while less weight was
specific to female patients. Prevalence of hypertension
and diabetes were noticeable higher among subjects with
reduced eGFR for both genders, and the usages of
anti-hypertensive, anti-diabetic and lipid-lowering drug
were more popular in reduced eGFR group. Concordantly,
the prevalence of cardiovascular and kidney diseases his-
tory showed dramatic augmentation in eGFR reduction
patients of both genders. Within our expectation, patients
with reduced eGFR of both genders experienced pro-
nounced increment of CMI, VAI as well as LAP.
Quartile analyses revealed gradient correlation between
CMI and prevalence of reduced eGFR, as displayed in
Fig. 1. When comparing the top quartile with the bottom
one, males exhibited a 6.0-fold change for the probability
of eGFR reduction while females showed a higher fold
change of 8.2. Both genders confirmed linear trends of
prevalent eGFR reduction across quartiles of CMI (all P
for trend< 0.001).
Results of linear regression analyses identified robust
negative association between CMI with eGFR. As
presented in Table 2, logarithmic likelihood ratio test
identified the association between CMI and eGFR was
non-linear in both genders after adjustment of age, race,
education level, family annual income, diet score, phys-
ical activity, current smoking, alcohol intake, hyperten-
sion, diabetes, antihypertensive drug, antidiabetic drug,
lipid-lowering drug, history of cardiovascular and kidney
diseases. In the full model of males, the two-piecewise
linear model revealed a rapid decrease of eGFR value
along with the early increase of normalized CMI, with a
β value of − 3.150 (− 3.589, − 2.712). However, when nor-
malized CMI reached 1.113 (equaled to 1.210 of CMI),
the change of eGFR shifted to a mild increase, with a β
value of 1.906 (0.675, 3.138). Similarly, in the complete
model of females, the eGFR also suffered a loss of
2.411 ml/min per 1.73m2 for each SD increase of CMI
before normalized CMI arrived to 1.472 (equaled to
1.520 of CMI). But after that, the eGFR began to have a
increment of 2.268 ml/min per 1.73m2 along with every
single unit increase of normalized CMI.
Logistic regression analyses confirmed the intensive
relationship between CMI with reduced eGFR, the re-
sults were arranged in Table 3. In males, per 1 SD in-
crease of CMI still caused 52% of additional risk for
eGFR reduction after adjusting all included cofounders.
When divided into quartiles, highest quartile of CMI
displayed 4.2 times risk for developing eGFR decrement
compared with lowest category in the full model, and
there was a significant linear trend for the risk of eGFR
reduction across the quartiles of CMI (P for trend< 0.001).
Similar results were observed in female participants,
risk of eGFR reduction got an elevation of 34.7% for
every single SD increment of CMI. Furthermore, the
ORs for top quartile compared with bottom group was
3.442 (1.685–7.031), and the linear trend across quar-
tiles also existed (P for trend< 0.001). We further
conducted a test for the interaction between genders
and CMI, and the results displayed to be insignificant,
identifying the robust association between CMI and re-
duced eGFR across genders.
ROC analyses showed a significant AUC value of CMI
for discriminating eGFR reduction, the results were
summarized in Table 4. In males, our findings displayed
that CMI possessed the greatest AUC (AUC: 0.633, 95%
CI: 0.620–0.646) among various indexes, statistically sig-
nificantly higher than that of LAP (AUC 0.633 vs. 0.606,
P = 0.036) and BMI (AUC 0.633 vs. 0.544, P = 0.004),
and there was also a trend for CMI to be superior than
VAI (0.627, 0.614–0.640). Meanwhile, CMI showed a
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Table 1 Characteristics of participants with reduced eGFR stratified by sex
Variables Males (n = 5360) Females (n = 6218)
Reduced eGFR (n = 90) Normal eGFR (n = 5270) P value* Reduced eGFR (n = 155) Normal eGFR (n = 6063) P value*
Age (years) 68.78 ± 10.41 54.11 ± 10.64 < .001 68.69 ± 8.87 52.99 ± 10.08 < .001
Race (Han) (%) 87 (96.7) 4987 (94.6) 0.394 152 (98.1) 5747 (94.8) 0.068
Education level (%) < .001 < .001
Primary school or below 57 (63.3) 2177 (41.3) 135 (87.1) 3398 (56.0)
Middle school 26 (28.9) 2487 (47.2) 18 (11.6) 2187 (36.1)
High school or above 7 (7.8) 606 (11.5) 2 (1.3) 478 (7.9)
Income level (CNY) (%) < .001 < .001
≤ 5000 28 (31.1) 693 (13.1) 41 (26.5) 680 (11.2)
5000 – 20,000 45 (50.0) 2827 (53.6) 77 (49.7) 3361 (55.4)
> 20,000 17 (18.9) 1750 (33.2) 37 (23.9) 2022 (33.3)
Diet score 2.24 ± 0.96 2.55 ± 1.10 0.008 1.68 ± 1.03 2.15 ± 1.11 < .001
Physical activity (%) < .001 < .001
Low 52 (57.8) 1158 (22.0) 100 (64.5) 2133 (35.2)
Middle 36 (40.0) 3817 (72.4) 42 (27.1) 3587 (59.2)
High 2 (2.2) 295 (5.6) 13 (8.4) 343 (5.7)
Current smoking (%) 28 (31.1) 3030 (57.5) < .001 43 (27.7) 987 (16.3) < .001
Current alcohol intake (%) 14 (15.6) 2421 (45.9) < .001 3 (1.9) 180 (3) 0.452
FPG (mmol/L) 5.74 (5.35 – 6.67) 5.60 (5.22 – 6.09) 0.010 5.78(5.30 – 7.05) 5.49 (5.12 – 5.99) < .001
Serum uric acid (μmol/L) 447.52 ± 122.56 331.80 ± 81.34 < .001 363.21 ± 94.01 253.06 ± 64.66 < .001
TG (mmol/L) 1.41 (1.10 – 2.07) 1.22 (0.86 – 1.88) 0.006 1.86 (1.30 – 2.55) 1.24 (0.89 – 1.88) < .001
HDL-C (mmol/L) 1.21 ± 0.27 1.41 ± 0.42 < .001 1.35 ± 0.41 1.41 ± 0.34 0.018
TG/HDL-C 1.19 (0.80 – 2.11) 0.91 (0.57 – 1.57) < .001 1.42 (0.92 – 2.24) 0.92 (0.59 – 1.51) < .001
SBP (mmHg) 161.58 ± 26.32 143.36 ± 22.43 < .001 154.16 ± 26.14 139.79 ± 23.87 < .001
DBP (mmHg) 89.01 ± 16.20 83.69 ± 11.71 0.003 82.57 ± 14.77 80.52 ± 11.41 0.088
Height (cm) 164.08 ± 5.56 166.46 ± 6.35 < .001 152.91 ± 5.91 155.69 ± 6.06 < .001
Weight (kg) 68.52 ± 12.06 68.61 ± 11.10 0.940 58.08 ± 10.64 60.33 ± 10.11 0.006
BMI (kg/m2) 25.36 ± 3.65 24.72 ± 3.54 0.091 24.77 ± 3.95 24.86 ± 3.76 0.778
WC (cm) 87.05 ± 10.36 83.74 ± 9.75 0.003 84.07 ± 10.37 81.20 ± 9.71 < .001
WHtR 0.53 ± 0.06 0.50 ± 0.06 < .001 0.55 ± 0.07 0.52 ± 0.06 < .001
hypertension (%) 74 (82.2) 2818 (53.5) < .001 120 (77.4) 2907 (47.9) < .001
diabetes (%) 22 (24.4) 508 (9.6) < .001 41 (26.5) 629 (10.4) < .001
Anti-hypertensive drug (%) 50 (55.6) 641 (12.2) < .001 73 (47.1) 989 (16.3) < .001
Anti-diabetic drug (%) 13 (14.4) 148 (2.5) < .001 20 (12.9) 278 (4.6) < .001
Lipid-lowering drug (%) 7 (7.8) 159 (3.0) 0.021 12 (7.7) 202 (3.3) 0.003
history of CVD (%) 46 (51.1) 781 (14.8) < .001 62 (40.0) 1092 (18.0) < .001
history of kidney disease 5 (5.6) 60 (1.1) < .001 11 (7.1) 77 (1.3) < .001
eGFR (ml/min per 1.73m2) 54.81 (46.46 – 57.67) 95.44 (87.00 – 103.44) < .001 52.90 (46.89 – 57.47) 93.23 (82.89 – 103.29) < .001
LAP (cm·mmol/L) 31.88 (18.63 – 51.35) 21.79 (10.62 – 43.35) 0.001 44.94 (26.00 – 77.56) 27.84 (16.00 – 50.25) < .001
VAI 1.51 (1.00 – 2.60) 1.12 (0.68 – 1.98) < .001 2.68 (1.78 – 4.17) 1.67 (1.06 – 2.78) < .001
CMI 0.62 (0.41 – 1.10) 0.45 (0.27 – 0.82) < .001 0.81 (0.49 – 1.26) 0.47 (0.29 – 0.81) < .001
Data are expressed as mean ± standard deviation(SD) or median (interquartile range) and numbers (percentage) as appropriate. Income level: family annual
income; CNY Chinese currency (1CNY = 0.15 USD), SBP systolic blood pressure, DBP diastolic blood pressure, FPG fasting plasma glucose, CVD cardiovascular
disease, includes coronary heart disease, arrhythmia, heart failure, and stroke; Kidney disease: includes nephritis, kidney dysfunction, renal stones, renal tumor,
and autoimmune kidney disease. Body mass index; WC waist circumference, WHtR waist-to-height ratio, TG triglyceride, HDL-C high density lipoprotein
cholesterol, TG/HDL-C triglyceride to high density lipoprotein cholesterol ratio, eGFR estimated glomerular infiltration rate, LAP lipid accumulation product,
VAI visceral adiposity index, CMI cardiometabolic index
*Comparisons of category variables between groups were tested by chi-square test or rank-sum test (ordinal category variables) and comparisons for
continuous variables between groups were tested by Student’s t or Mann-Whitney test
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sensitivity of 88.9% and a specificity of 37.1%. In fe-
males, CMI had an AUC (AUC: 0.684, 95% CI: 0.672–
0.695) which was comparable to that of VAI (AUC: 0.688,
95% CI: 0.676–0.699, P value for difference = 0.148) and
statistically significantly greater than that of LAP (AUC
0.684 vs 0.660, P = 0.047), WC (AUC 0.684 vs 0.588,
P < 0.001) and BMI (AUC 0.684 vs 0.500, P < 0.001). Fur-
thermore, CMI exhibited the greatest sensitivity (89.0%) in
this gender. However, the specificity was still low and was
given to 39.8%.
Discussion
Our study showed that in this large, community-based
cohort of middle-aged Chinese individuals, CMI, a
novel measure of VAT, was independently and robustly
associated with the presence of reduced eGFR in both
genders. CMI could reflect not only VAT but also patho-
logic process that resulted in impaired kidney function,
thus provided a clinical clue for related basic researches.
As our results revealed the potential of CMI as a screen-
ing marker of reduced eGFR, further understanding of the
underlying pathophysiology should improve strategies to
prevent and potentially reverse detrimental kidney failure
and cardiovascular outcomes, especially in people with
poor socioeconomic conditions.
Dyslipidemia is a condition that always appears in the
development of CKD, even in the early stage of eGFR
reduction, and the major components of dyslipidemia in
CKD has been revealed to be increased TG level and
decreased HDL-C level [7]. Indexes that represent this
specific pattern has been identified to have a strong correl-
ation with CKD. For instance, Hou et al. revealed that TG
level was closely associated with mildly decreased eGFR
even among middle aged or elderly Chinese population. It
was worthy to note that this relationship existed when TG
level was still in the normal range. This finding gave us an
implication that increased TG level could appear in the
early process of decreased eGFR [9]. Lee et al. identified
hypertriglyceridemia as an independent risk factor of pro-
gressed CKD, confirmed the association persistent in mid-
dle and late stage of CKD [11]. Furthermore, Tozawa et al.
and Shimizu et al. provided compelling evidences that TG
had an independent effect to increase the risk of eGFR
decrement from longitudinal studies, Tozawa et al. also
identified HDL-C positively related to eGFR value and re-
vealed TG had an impact on the development of protein-
uria [10, 40]. Apart from above investigations, researches
also identified the utility of TG/HDL-C in identifying
eGFR reduction as it incorporated both TG and HDL-C
level. Ho et al. demonstrated the correlation between TG/
HDL-C with CKD, and Wen et al. even showed the advan-
tage of TG/HDL-C when compared with TG alone with
respect to the development of CKD, confirmed our afore-
mentioned hypothesis [13, 14]. However, there was one
point that worth to be mentioned, although TG/HDL-C
had a robust association with CKD, it was not an ideal
marker of eGFR reduction due to its low sensitivity and
specificity [13].
As another condition that always accompany with
CKD, obesity is related to multiple risk factors of CKD,
such as hypertension and diabetes [41, 42]. Its direct
association with CKD has been evaluated through in-
dexes. As the most widely used index of obesity, BMI
has already been elucidated to have a connection with
new-onset CKD, CKD progression and end stage renal
failure [16, 17, 43]. However, since BMI do not consider
adipose tissue distribution, there is no doubt that BMI is
unsuitable for reflecting the relationship between obesity
phenotype with CKD. Therefore, indexes of abdominal
Fig. 1 The prevalence of reduced eGFR by quartiles of CMI.
Prevalent decreased eGFR increased proportionally across ascending
quartiles of CMI in both genders (P for trend< 0.05). Abbreviations:
CMI, cardiometabolic index; eGFR: estimated glomerular
filtration rate
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obesity such as WC and WHtR have been widely investi-
gated for their associations with CKD. Among them,
WHtR was found to have greatest application potential
for detecting CKD by several studies [19, 20]. Theoretic-
ally, by using height to standardize WC value, WHtR
was design to be a superior reflection of abdominal
obesity since people with different height were supposed
to have different standard WC value. Nevertheless, stud-
ies did not support any of these indexes to be an eligible
marker with great sensitivity or specificity for detection
of reduced eGFR [19–22]. Meanwhile, studies found that
VAT contributed more to CKD than SAT [23]. Indexes
like WC hadd no power to distinguish VAT from SAT
alone but could recognize VAT correctly when working
together with TG [24, 44]. Taking all above messages to-
gether, we can speculate that indexes contain informa-
tion about dyslipidemia and abdominal obesity should
do better in the identification of VAI and be able to re-
fine the recognition of eGFR reduction.
Indexes that integrate both abdominal obesity and dys-
lipidemia has been proposed. Determined by WC and TG
levels, LAP was put forward for recognizing cardiovascu-
lar risk [33], and it has also been identified to possess a
stronger association with CKD than BMI, WC and WHtR
[45]. Later, a concept named VAI was posited as an indica-
tor of cardiometabolic risk with an additional consider-
ation of HDL-C and BMI when compared with LAP [34].
In recent studies, VAI showed strong association with
Table 2 Evaluation of the impact of CMI on eGFR value with the use of piecewise linear regressiona
Unadjusted MV adjusted
Males
Linear model β Value (95% CI) P value −1.850 (−2.259, −1.440) < 0.001 −2.214 (−2.561, −1.866) < 0.001
Non-linear model Breakpoint (K) 1.024 1.113
β 1 (<K) (95% CI) P value −3.324 (−3.863, − 2.786) < 0.001 −3.150 (−3.589, − 2.712) < 0.001
β 2 (>K) (95% CI) P value 3.777 (2.371, 5.182) < 0.001 1.906 (0.675, 3.138) 0.002
Logarithmic likelihood ratio test P value < 0.001 < 0.001
Females
Linear model β Value (95% CI) P value −4.046 (−4.438, −3.654) < 0.001 −1.914 (−2.262, − 1.566) < 0.001
Non-linear model Breakpoint (K) 1.34 1.472
β 1 (<K) (95% CI) P value −5.001 (−5.472, −4.530) < 0.001 −2.411 (− 2.813, − 2.010) < 0.001
β 2 (>K) (95% CI) P value 2.478 (0.636, 4.320) 0.008 2.268 (0.547, 3.988) 0.010
Logarithmic likelihood ratio test P value < 0.001 < 0.001
Abbreviations: CMI cardiometabolic index, OR odds ratio, 95% CI 95% confidence interval. Linear model: model that presumes the association between CMI and
eGFR is linear. Non-linear model: model that presumes the association between CMI and eGFR is non-linear and has breakpoint. Unadjusted: no adjustment; MV
adjusted: multivariable adjusted model, includes age, race, education level, family annual income, physical activity, current smoking, current alcohol intake,
hypertension, diabetes, antihypertensive drug, antidiabetic drug, lipid-lowering drug, history of cardiovascular disease and kidney disease. aTwo-step linear
regression model was applied to explore the non-linear association between CMI and eGFR
Table 3 Sex-specific logistic regression models for reduced eGFR with CMI
Males Females P for
interactionUnadjusted OR
(95% CI)
P value MV adjusted OR
(95% CI)
P value Unadjusted OR
(95% CI)
P value MV adjusted OR
(95% CI)
P value
CMI (Per 1 SD
increase)
1.467 (1.211, 1.777) < 0.001 1.516 (1.182, 1.943) 0.001 1.760 (1.519, 2.040) < 0.001 1.347 (1.122, 1.618) 0.001 0.172
Quartiles of CMI
Quartile 1 1.000 1.000 1.000 1.000
Quartile 2 3.711 (1.500, 9.182) 0.005 2.717 (1.061, 6.957) 0.037 2.835 (1.372, 5.856) 0.005 2.285 (1.069, 4.888) 0.033
Quartile 3 5.092 (2.112, 12.273) < 0.001 3.867 (1.551, 9.640) 0.004 4.187 (2.090, 8.387) < 0.001 2.509 (1.204, 5.225) 0.014
Quartile 4 5.439 (2.267, 13.052) < 0.001 4.227 (1.681, 10.627) 0.002 7.939 (4.091, 15.408) < 0.001 3.442 (1.685, 7.031) < 0.001
P value for
trend
< 0.001 0.001 < 0.001 < 0.001
MV indicates multivariable, OR odds ratio, CI confidence interval, CMI cardiometabolic index. Cut points for CMI: Men: ≤ 0.27, > 0.27 and ≤ 0.46, > 0.46 and ≤ 0.83,
> 0.83; Women: ≤ 0.30, > 0.30 and ≤ 0.48, > 0.48 and ≤ 0.82, > 0.82. MV model adjusted for age, race, education level, family annual income, diet score, physical
activity, current smoking, current alcohol intake, hypertension, diabetes, antihypertensive drug, antidiabetic drug, lipid-lowering drug, history of cardiovascular
disease (coronary heart disease, arrhythmia, heart failure, and stroke) and kidney disease (nephritis, kidney dysfunction, renal stones, renal tumor, and
autoimmune kidney disease)
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CKD and greater potential as a marker of eGFR reduction
than LAP as well as traditional anthropometric indexes
[45, 46]. However, these two novel indexes still have limi-
tations. Both LAP and VAI have sex-specific equations,
and VAI has a sophisticated algorithm, these will increase
the complexity of calculation. As for LAP, information
about HDL-C is not utilized, which is an important aspect
of dyslipidemia in CKD. Moreover, height info is also
wasted by LAP, but people with different height should
have different WC standard. Last but not least, although
VAI possessed a greater discriminative power than LAP
and other indexes, it still failed to reach satisfying sensitiv-
ity and specificity values, thus its value for becoming a
marker of eGFR reduction is limited [46].
CMI is a young index which was posited by Ichiro
Wakabayashi in 2015 [25]. Different from LAP and VAI, it
reflects both characteristics of dyslipidemia in CKD and
accurate central obesity status through a simple, general-
ized eq. CMI has also been identified to correlate with
multiple cardiovascular risk factors, implicated to have a
great potential in screening related diseases [25–29]. Since
many of these diseases has been identified to be risk fac-
tors of CKD [16, 47–50], we hypothesize that CMI corre-
lates with reduced eGFR and is capable of being a premier
indicator of eGFR decrement. In our present study, re-
gression analyses revealed the intensive and direct associa-
tions of CMI with eGFR value and eGFR reduction in
both genders, confirming above hypothesis. Moreover, we
observed a breakpoint in the association between CMI
and eGFR value, which meant the change of eGFR shifted
from decrease to increase after CMI reached certain value.
And this phenomenon was robust and persistent across
genders. Although the exact mechanism underlying this
paradoxical phenomenon is still unclear, some previous
findings can also give us a clue for possible explanations.
While obesity was commonly considered to associate with
the decline of eGFR [8, 15], studies also found a protective
effect of obesity on CKD patients [51, 52], and this pro-
tective effect could be explained by the evidence that ex-
cessive adipose tissue might temper the deleterious effects
of inflammatory factors by sequestering them [53, 54].
Consistent with this theory, the breakpoint was located at
high levels of CMI (> 75 percentile) in each gender, which
meant that the protective effect became more predomin-
ant than the destructive effect only when fatty tissue
accumulated to a sufficient volume. Another possible ex-
planation was the residual confounders. Although we had
adjusted several factors that related to CMI and eGFR,
there were still some confounders that we did not take
into our regression equations. Therefore, some uncovered
confounding factors could influence our results and
caused this paradox. In order to validate the paradox
founded in the present study, studies with prospective de-
sign and consideration of more modifiers are needed in
the future.
Further, we confirmed the association between CMI
and reduced eGFR was positive and strong. We found
that the risk of reduced eGFR was proportionally in-
creased across the quartiles of CMI, which was different
from the breakpoint phenomenon in the association be-
tween CMI and eGFR value. Given that the breakpoint
of CMI located behind the 75 percentile in both genders,
we could easily figure out that the limited increase of
eGFR in CMI levels above the breakpoint has minimal
effect on the whole inverse trend of CMI with reduced
kidney function (eGFR< 60 ml/min per 1.73m2). We also
Table 4 AUC for indexes to discriminate eGFR reduction in females and males
Variables AUC (95%CI) P value Cut-off according to Youden’s index Sensitivity (%) Specificity (%)
Males
CMI 0.633 (0.620–0.646)a,c < 0.001 > 0.35 88.9% 37.1%
VAI 0.627 (0.614–0.640)c < 0.001 > 0.83 90.0% 34.7%
LAP 0.606 (0.593–0.619)c < 0.001 > 18.33 77.8% 43.6%
WC 0.589 (0.576–0.602)c 0.001 > 79.1 83.3% 35.0%
BMI 0.544 (0.531–0.558) 0.135 > 22.02 88.9% 22.8%
Females
CMI 0.684 (0.672–0.695)a,b,c < 0.001 > 0.39 89.0% 39.8%
VAI 0.688 (0.676–0.699)a,b,c < 0.001 > 1.69 80.0% 50.4%
LAP 0.660 (0.648–0.672)b,c < 0.001 > 36.12 65.2% 61.8%
WC 0.588 (0.576–0.600)c < 0.001 > 84.20 52.9% 64.0%
BMI 0.500 (0.488–0.513) 0.995 ≤ 27.81 76.1% 20.1%
Abbreviations: AUC area under the ROC curve, 95% CI 95% confidence interval, CMI cardiometabolic index, VAI visceral adiposity index, LAP lipid accumulation
product, WC waist circumference, BMI body mass index
aindicates a significant larger as compared to LAP;
bindicates a significant larger as compared to WC;
cindicates a significant larger as compared to BMI
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noticed that males had a slightly higher risk of develop-
ing reduced eGFR when compared with their female
counterparts. But the interaction test revealed that this
disadvantage was statistically insignificant. However, al-
though we could not conclude that males were under
greater risk of reduced eGFR, we still elucidated that
CMI had a robust association with eGFR reduction in
both genders, identifying the utility and stability of CMI
for the risk stratification of reduced eGFR.
Findings from ROC analyses provided compelling evi-
dence for CMI to be a screening marker of CKD. In
males, CMI possessed greatest AUC value, although it
did not have a significant larger discriminating ability
than VAI, the simple and generalized equation for both
sexes would be a vantage. With a sensitivity of 88.9%,
CMI demonstrated its capability to function well in the
screening test, since more suspicious patients should be
positive in this kind of examination. It was worthy to
note that neither of CMI, VAI and LAP had a significant
greater AUC than WC, which was beyond our expect-
ation, this could be explained by the lacking of sample
size since the absolute number and prevalence of re-
duced eGFR were much lower in males than in females.
Further studies are needed to validate this intriguing
finding. In females, CMI did an even better job as it per-
formed better than other indexes significantly except
VAI. Although exhibited a negligible disadvantage in dis-
criminating eGFR reduction, CMI showed a much
higher sensitivity than VAI, thus the applicative value for
CMI was still superior than VAI among females. In con-
clusion, with great discriminative ability and high sensi-
tivity value, CMI showed its potential for becoming an
economic screening marker to filter out people with re-
duced eGFR.
Mounting evidence has emerged to reveal the mech-
anism under the association between CMI with CKD.
First, mechanism of dyslipidemia in CKD has already
been elucidated. Hypertriglyceridemia is a multifactorial
phenomenon, and is partially due to diminished catab-
olism. This reduction is an outcome of depressed lipo-
protein lipase (LPL) activity, which is responsible for
the hydrolysis of TG [55]. And the decreased LPL activ-
ity has been identified to be caused by secondary hyper-
parathyroidism induced insulin resistance (IR) and
excess of lipase inhibitors like apolipoprotein (Apo)
C-III in the progression of CKD [56, 57]. For another
aspect, hepatic Apo A-I gene expression and hepatic
lecithin cholesterol acyl transferase (LCAT) mRNA ex-
pression are downregulated during the course of CKD,
and then this change attributes to a lower plasma Apo
A-I level and decreased LCAT activity [58, 59]. Since
Apo A-I is an essential functional component of
HDL-C [60], the concentration of HDL-C in blood is
consequently decreased. Similarly, the normal function
of HDL-C is also impaired because of inadequate LCAT
activity, which is important in the process of transport-
ing cholesterol to HDL in peripheral tissues [60].
Second, basic research has also revealed the intrinsic
mechanism between obesity with CKD. Adipocytes
produce a series of factors, such as angiotensinogen,
precursor of angiotensin II and leptin, which may
trigger glomerular hypertension through local renin-
angiotensin-aldosterone system (RAAS) or sympathetic
system, then leading to the decrease of eGFR [8]. Further-
more, inflammation involves in the association between
obesity with CKD as well, macrophages are found to accu-
mulate in the kidney of obese animals in the effect of
angiotensin [61]. Some inflammatory cytokines such as
interleukin-6 (IL-6) and Tumor necrosis factor-α (TNF-α)
have also been implicated in obesity-related CKD [62].
Therefore, obesity could promote the progression of renal
disease through several, partially overlapping mechanisms.
Sum up above two points, as composites of CMI, dyslipid-
emia and obesity have experiment confirmed relationship
with CKD. Thus, the association between CMI with re-
duced eGFR observed in our study has a concrete founda-
tion from basic researches.
There are still some limitations in our study that
needed to be mentioned. First, due to the cross-sectional
design, our work can only provide evidence about the
strong association between CMI and reduced eGFR, but
information about the causality of this relationship need
further prospective studies to confirm. Second, it has an
inherent limitation of not being a randomized study. Al-
though multivariable adjustments were performed for
potential confounding factors, a possible effect of un-
measured variables such as C-reactive protein cannot be
excluded. Third, our study participants were recruited
from rural area of northeast of China, whether the re-
sults can be applied to populations of different areas or
races require more studies to investigate. Finally, our
diagnosis based on a single biochemistry test, the cre-
atinine value could be influenced by uncertain factors,
thus the accuracy of eGFR could be mildly disturbed.
Conclusions
In summary, our work was the first study to reveal the
relationship between CMI and reduced eGFR which was
independent of prevalent CVD, medication used, and
conventional cardiovascular risk factors. Thus, these data
provide strong evidence of a unique, independent and
economic role of CMI in a high burden of kidney disease.
These findings have important implications for guiding
primordial prevention and understanding the mechanisms
underlying VAT-mediated renal injury.
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